3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Melanoma
71
Neoplasms
10
Skin Neoplasms
5
Neoplasm Metastasis
5
Colorectal Neoplasms
2
Brain Neoplasms
2
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Skin Diseases
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Multiple Myeloma
1
Laryngeal Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Hematologic Neoplasms
1
Glioma
1
Erdheim-Chester Disease
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Drug Therapy
2
pembrolizumab
1
motexafin gadolinium
1
cobimetinib
1
cabozantinib
1
Vemurafenib
1
Specimen Handling
1
Ritonavir
1
Radiotherapy
1
Quality of Life
1
Patient Reported Outcome Measures
1
Observation
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
Indinavir
1
Immunotherapy
1
Doxorubicin
1
Biopsy
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Laryngeal Neoplasms
×
Vemurafenib
×
Dermatologic
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled